APA

Yu E., Miotto K., Akerele E., Montgomery A., Elkashef A., Walsh R., Montoya I., Fischman M. W., Collins J., McSherry F., Boardman K., Davies D. K., O'Brien C. P., Ling W., Kleber H. & Herman B. H. (20081216). A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. : Drug and alcohol dependence.

Chicago

Yu Elmer, Miotto Karen, Akerele Evaristo, Montgomery Ann, Elkashef Ahmed, Walsh Robert, Montoya Ivan, Fischman Marian W, Collins Joseph, McSherry Frances, Boardman Kathy, Davies David K, O'Brien Charles P, Ling Walter, Kleber Herbert and Herman Barbara H. 20081216. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. : Drug and alcohol dependence.

Harvard

Yu E., Miotto K., Akerele E., Montgomery A., Elkashef A., Walsh R., Montoya I., Fischman M. W., Collins J., McSherry F., Boardman K., Davies D. K., O'Brien C. P., Ling W., Kleber H. and Herman B. H. (20081216). A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. : Drug and alcohol dependence.

MLA

Yu Elmer, Miotto Karen, Akerele Evaristo, Montgomery Ann, Elkashef Ahmed, Walsh Robert, Montoya Ivan, Fischman Marian W, Collins Joseph, McSherry Frances, Boardman Kathy, Davies David K, O'Brien Charles P, Ling Walter, Kleber Herbert and Herman Barbara H. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. : Drug and alcohol dependence. 20081216.